An ongoing Phase Ib/II clinical trial investigating APR-246 combined with Azacitidine in adults with TP53-mutated MDS and oligoblastic AML (≤30% blasts) was recently presented at the 2019 American Society of Hematology annual meeting (NCT03072043). Here, TP53 is linked to myelodysplastic syndrome.